Ugurel S - Search Results

1

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.

Salzmann M, Pawlowski J, Loquai C, Rafei-Shamsabadi DA, Meiss F, Ugurel S, Schadendorf D, Meier F, Enk AH, Hassel JC. Salzmann M, et al. Among authors: ugurel s. Eur J Cancer. 2022 May;166:24-32. doi: 10.1016/j.ejca.2022.02.008. Epub 2022 Mar 7. Eur J Cancer. 2022. PMID: 35272084

2

Dose-dependent severe cutaneous reactions to imatinib.

Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Ugurel S, et al. Br J Cancer. 2003 Apr 22;88(8):1157-9. doi: 10.1038/sj.bjc.6600893. Br J Cancer. 2003. PMID: 12698177 Free PMC article.

3

Systemic treatment in advanced melanoma: innovative perspectives.

Ugurel S, Schadendorf D. Ugurel S, et al. Onkologie. 2003 Jun;26(3):234-8. doi: 10.1159/000071618. Onkologie. 2003. PMID: 12845207 Review.

4

Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients.

Ugurel S, Uhlig D, Pföhler C, Tilgen W, Schadendorf D, Reinhold U. Ugurel S, et al. Cancer Immunol Immunother. 2004 Jun;53(6):551-9. doi: 10.1007/s00262-003-0489-1. Epub 2004 Jan 16. Cancer Immunol Immunother. 2004. PMID: 14727087 Free PMC article.

5

Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

Ugurel S, Lindemann M, Schadendorf D, Grosse-Wilde H. Ugurel S, et al. Cancer Immunol Immunother. 2004 Nov;53(11):1051. doi: 10.1007/s00262-004-0565-1. Epub 2004 Jun 30. Cancer Immunol Immunother. 2004. PMID: 15232653 Free PMC article. No abstract available.

6

Immunogenicity of constitutively active V599EBRaf.

Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröcker EB, Straten Pt, Rapp UR, Becker JC. Andersen MH, et al. Among authors: ugurel s. Cancer Res. 2004 Aug 1;64(15):5456-60. doi: 10.1158/0008-5472.CAN-04-0937. Cancer Res. 2004. PMID: 15289355

7

Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.

Fink W, Zimpfer-Rechner C, Thoelke A, Figl R, Kaatz M, Ugurel S, Schadendorf D. Fink W, et al. Among authors: ugurel s. Onkologie. 2004 Dec;27(6):540-4. doi: 10.1159/000081335. Onkologie. 2004. PMID: 15591712 Clinical Trial.

8

Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.

Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. Bloethner S, et al. Among authors: ugurel s. Carcinogenesis. 2005 Jul;26(7):1224-32. doi: 10.1093/carcin/bgi066. Epub 2005 Mar 10. Carcinogenesis. 2005. PMID: 15760917

9

Lack of clinical efficacy of imatinib in metastatic melanoma.

Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D. Ugurel S, et al. Br J Cancer. 2005 Apr 25;92(8):1398-405. doi: 10.1038/sj.bjc.6602529. Br J Cancer. 2005. PMID: 15846297 Free PMC article. Clinical Trial.

10

Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.

Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Ugurel S, et al. Int J Cancer. 2005 Dec 10;117(5):825-30. doi: 10.1002/ijc.21073. Int J Cancer. 2005. PMID: 15957165 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page